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Background. Alcoholic liver disease has emerged as 
a leading indication for hepatic transplantation, al-
though it is a controversial use of resources. We aimed 
to examine all aspects of liver transplantation associ-
ated with alcohol abuse. 
Methods. Retrospective cohort analysis of 123 alco-
holic patients with a median of 7 years follow-up at 
one center. 
Results. In addition to alcohol, 43 (35%) patients had 
another possible factor contributing to cirrhosis. Actu-
arial patient and graft survival rates were, respectively, 
84% and 81 % (1 year); 72% and 66% (5 years); and 63% and 
59% (7 years). Mter transplantation, 18 patients (15%) 
manifested 21 noncutaneous de novo malignancies, 
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which is significantly more than controls (P=O.OOOI); 
upper aerodigestive squamous carcinomas were over-
represented (P=O.03). Thirteen patients had definitely 
relapsed and three others were suspected to have re-
lapsed. Relapse was predicted by daily ethanol con-
sumption (P=O.0314), but not by duration of pretrans-
plant sobriety or explant histology. No patient had 
alcoholic hepatitis after transplantation and neither 
late onset acute nor chronic rejection was significantly 
increased. Multiple regression analyses for predictors of 
graft failure identified major biliary/vascular complica-
tions (P=O.OI), chronic bile duct injury on biopsy 
(P=O.OO2), and pericellular fibrosis on biopsy (P=O.05); 
graft viral hepatitis was marginally significant (P=O.07) 
on univariate analysis. 
Conclusions. Alcoholic liver disease is an excellent 
indication for liver transplantation in those without 
coexistent conditions. Recurrent alcoholic liver dis-
ease alone is not an important cause of graft pathology 
or failure. Potential recipients should be heavily 
screened before transplantation for coexistent condi-
tions (e.g., hepatitis C, metabolic diseases) and other 
target-organ damage, especially aerodigestive malig-
nancy, which are greater causes of morbidity and mor-
tality than is recurrent alcohol liver disease. 
INTRODUCTION 
Hepatic transplantation is an accepted standard of care for 
end-stage liver disease. One-year survival rates approach 
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80% to 85% and late graft loss from chronic rejection is 
uncommon (1). Unfortunately, recurrence ofthe original dis-
ease is emerging as a major problem, affecting most viral 
hepatitis patients and 15% to 25% of those with autoimmune 
liver diseases within 5 years (2, 3). End-stage alcoholic liver 
disease may be an excellent indication for transplantation, 
because short-term survival rates are comparable with other 
indications (4-6), and drinking relapse can potentially be 
controlled. 
Indeed, alcoholic liver disease has emerged as a leading 
indication for transplantation (7), although it is a controver-
sial use of resources (8) because the original disease and 
recurrence require "deliberate" patient activity. Studies of 
alcoholic liver transplant recipients have therefore justifiably 
focused on alcohol relapse, hoping to provide support for 
stringent pretransplant selection criteria that are intended 
to minimize disease recurrence. This approach, however, has 
deflected attention away from the impact of coexistent dis-
eases such as viral hepatitis and aerodigestive cancers. A 
holistic approach that addresses these issues is required. 
We undertook this retrospective cohort analysis (123 alco-
holic patients, median 7 years follow-up at one center) to 
examine all aspects of liver transplantation associated with 
alcohol abuse. We aimed to better define the impact of past 
alcohol use, associated diseases, and drinking relapse on 
survival and graft disease. 
METHODS 
Data Collection 
Between January 1991 and December 1992, 123/513 (24%) pri-
mary liver allograft recipients at the University of Pittsburgh had a 
diagnosis of alcoholic liver disease. The diagnosis was determined 
from a consensus of surgical, hepatological, and psychiatric evalua-
tions; patients had a history of sustained excessive alcohol use (nor-
maliy;;::20 g ethanol/day, women; ;;::60 g ethanol/day, men) with a 
diagnosis of alcohol abuse or dependence after psychiatric evaluation 
in conjunction with laboratory data. Before abstinence, most pa-
tients drank on a daily basis; for others, the average weekly alcohol 
usage was converted into average daily drinks for comparison. Daily 
alcohol consumption, by patient report, was converted to grams of 
ethanol. For lifetime ethanol exposure, the average daily amount 
was multiplied by the duration of drinking. The criteria for trans-
plant eligibility that related to alcohol use were relatively liberal: 6 
months pretransplant sobriety, or rehabilitation, with exceptions in 
select cases. 
Pretransplant serology for hepatitis B and C (EIA-2) virus infec-
tion was available in 119 patients, the others were missing serology 
for hepatitis B (n=1), hepatitis C (n=2), and both hepatitis Band 
hepatitis C (n=1). Coexistent disease(s) were discovered primarily 
during examination of the native hepatectomy specimens and sero-
logic studies for viral hepatitis infection. A diagnosis of hemachro-
matosis was based on the presence of at least 3 + iron deposited 
primarily in biliary epithelial cells and hepatocytes, a pattern indic-
ative of hcmachromatosis. Cases with significant iron overload in 
nonparenchymal cells and peri septal hepatocytes were not included. 
A diagnosis of alpha-1-anti-trypsin deficiency was based on the pres-
ence oflarge (>4 microns) periodic acid-Schiff positive globules, after 
diastase digestion, which has been previously shown to correlate 
with <Xl-antitrypsin abnormalities (9). 
The histology slides from all native livers and allograft biopsies 
were reviewed, without knowledge ofthe clinical findings, and then 
correlated with clinical and radiological data to generate a record of 
patient follow-up. The necro-inflammatory activity and fibrosis stag-
ing were carried out according to the modified hepatitis activity 
index of Ishak et a!. (10) Allograft biopsies were performed for 
investigation of graft dysfunction. Three patients had no allograft 
biopsy. Fifty-two patients had allograft biopsies more than 6 months 
after transplant (including failed allografts). 
Alcohol relapse was defined as any alcohol use revealed by the 
patient after transplant, or ad hoc blood alcohol assays. All patients 
with abnormal monthly liver biochemistry were questioned about 
relapse, but there were no protocol prospective interviews or alcohol 
assays. Latest follow-up was taken to be date of death, graft failure, 
or the latest laboratory test. Where patients were retransplanted, 
data pertinent to the first graft was used for statistical analysis. A 
comparison group was generated from the other 390 patients receiv-
ing primary liver transplants during the same period. These studies 
were approved by the local institutional review board approval (pro-
tocol #2105PUHnew). 
Statistical Analyses 
Statistical analyses included basic descriptive statistics, chi-
square and non-parametric tests, and modeling techniques including 
logistic and Cox proportional hazards regression. All models compar-
ing those who underwent transplantation for alcoholic liver disease 
with the nonalcoholic group were fit adjusted for age, sex, and 
severity of illness (UNOS status) at the time of transplantation. 
Survival rates were obtained using the Kaplan Meier method. Time-
dependent covariates were used when appropriate. Analyses were 
performed using Statistical Analysis System for Windows (version 
6.12). 
RESULTS 
Pretransplantation Characteristics 
The study cohort contained 91 men and 32 women, of 
median age 53 years (range 28-75). All but one patient had 
cirrhosis. Alcohol was the only identified factor in 80 (65%), 
whereas 43 (35%) had another possible contributing factor; 
these included hepatitis C (20/120 tested, 17%), hepatitis B 
and acute acetaminophen toxicity without cirrhosis (1/121, 
0.8%), hemochromatosis (9[including one with cxl-anti-tryp-
sin deficiencyJ/123, 8%), cxl-anti-trypsin deficiency alone (4/ 
123,3%), sarcoidosis (11123, 0.8%), epithelioid granulomas of 
unknown cause (21123, 1.6%), and explant hepatitis in sero-
negative patients (see below, 61123 5%). Twelve patients 
(10%) had hepatocellular carcinoma (T2-T4), and one had an 
unsuspected peripheral cholangiocarcinoma. 
Complete pretransplant alcohol histories, including na-
ture, quantity, frequency, and duration of alcohol intake, 
were available for 110 patients (29 women, 81 men); the 
remainder had less complete but adequate documentation of 
excessive intake. Women reported alcohol consumption be-
fore transplant of median 93 glday (range 23-675 g/day), and 
men reported a median 140 g/day (range 23-955 g/day). The 
median estimated lifetime intake of alcohol was 408 kg 
(range 85-3572 kg) for women, and 638 kg (range 51-8038 
kg) for men. Men had a longer median duration of drinking 
than women (15 years vs. 12 years), whereas women had a 
longer median duration of pre transplant sobriety (26 months 
vs. 12 months). 
Native Liver Pathology Review 
Fifty-six of 123 native livers (45%) had features suggestive 
of alcoholic liver disease, including livers from 9 hepatitis 
C-infected patients (Table 1). These features included mi-
cronodular cirrhosis, perivenular pericellular fibrosis, cen-
tral-nodular Mallory's bodies (41 cases), and steatohepatitis 
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TABLE 1. Histologic determinations of prevalent injuries in 123 explanted native livers, relative to assessment of 
alcohol injury 
Histopathologic evidence for 
alcohol-related liver injury Number of patients 
Histopathology suspicious for 
HCVIHCV seropositive cases Histopathology of coexistent conditions (n) 
None/minimal 67 (54%) 9/11 (82%) 
Mild 25 (20%) 0/3 
Moderate/strong 31 (25%) 1/6 (17 %) 
hemochromatosis (3) 
al-antitrypsin deficiency (2) 
epithelioid granulomas, unknown cause (2) 
HBV + acute acetaminophen toxicity (1) 
? viral hepatitis, but seronegative (6) 
hemochromatosis (4a ) 
aI-antitrypsin deficiency (2) 
sarcoid (1) 
hemochromatosis (2) 
aI-antitrypsin deficiency (1) 
a One patient had evidence of both hemochromatosis and aI-antitrypsin deficiency. 
HCV, hepatitis C. 
(4 cases; always focal) (11). Twenty-three (34%) of the other 
67 livers without evidence of alcohol injury showed some 
other insult on histology (Table 1). Six native livers without 
alcohol injury showed chronic hepatitis, but were from pa-
tients with negative pretransplant viral serology. Neverthe-
less, four of the six patients went on to develop allograft viral 
hepatitis B or C after transplantation, suggesting that the 
pretransplant serology was false negative. If that assumption 
is made, then the explant histology did not indicate a cause of 
the cirrhosis in 441123 (36%) patients. 
Mallory's bodies (P=O.0044) and steatosis (P=0.0201) were 
more frequent in patients with shorter pretransplant sobri-
ety (Table 2). Steatohepatitis (4 cases) was too infrequent for 
correlation. 
Graft and Patient Survival after Transplantation 
Follow-up was available for all patients (median 2543 
days). Tables 3 and 4 detail causes of graft failure and death. 
Actuarial patient and graft survival rates were, respectively, 
84% and 81% (1 year), 83% and 80% (2 years), 72% and 66% 
(5 years), and 63% and 59% (7 years). Graft and patient 
survival did not differ significantly from controls trans-
planted during the same period (data not shown). Seventy-
one (57%) patients had functioning first allografts at latest 
follow-up (median 2647 days, range 1513-2931). Hepatocel-
lular carcinoma recurred in 3 of 12 patients (170, 260, 720 
days) and caused death. 
Extrahepatic Malignancy after Transplantation 
Excluding posttransplant lymphoproliferative disorders 
(PTLD), 27 patients developed 33 new malignancies after 
transplantation. This is significantly more than in nonalco-
holic controls (Table 5; P=O.OOOI). Eighteen patients (15%) 
manifested 21 noncutaneous malignancies, which is also sig-
nificantly more than controls (P=O.OOOI); in 7 patients the 
malignancy was fatal. The most common primary sites were 
upper aerodigestive, urogenital, lung, and colonic (Table 5). 
Upper aerodigestive squamous carcinomas were overrepre-
sented compared with controls (P=0.03). Twelve patients 
(10%) (including three with noncutaneous malignancies) de-
veloped cutaneous malignancy-none fatal. Three patients 
(2.5%) (including one with colonic adenocarcinoma) devel-
oped PTLD; it was fatal in two. 
TABLE 2. Correlation of duration of sobriety before 
transplantation with steatosis and Mallory's bodies in the 
explanted native liver 
Sobriety (months) 
1-6 
7-24 
>24 
Mallory's bodiesa 
18/32 (56%) 
9/41 (22%) 
11146 (24%) 
Steatosisb 
21/32 (66%) 
14141 (34%) 
19/46 (41%) 
Sobriety duration was known in 119 patients. Mallory's bodies: 
central nodular location required to eliminate examples due to chola-
testasis (a P=0.0044; b P=O.0201). The analysis was done using two 
different logistic regression models. Mallory bodies and steatosis 
were the two dichotomous outcomes and pretransplant sobriety was 
the independent variable. Thus, the one univariate model indicated 
that pretransplant sobriety does affect Mallory bodies, and the other 
univariate model indicated that pretransplant sobriety affects ste-
atosis. 
TABLE 3. Causes of death or graft failure in the first 6 
months after transplantation (first graft only) 
Number of Time range 
patients (days) 
Cause of death 
Cardiovascular 2 1-2 
Infection 9 21-159 
Graft; failure without death 
Primary nonfunction 4 0 
Hepatic artery thrombosis 2 6-15 
Alcohol Relapse: Incidence and Impact 
Thirteen patients had definite relapse, confirmed in eight 
by positive blood alcohol tests (on multiple occasions in four, 
and > 100 mg/dl in six), and admitted by five others. Three 
patients relapsed within 6 months after transplantation. 
Three additional patients had histology suspicious for re-
lapse, but without other evidence, and denied alcohol use. 
Logistic regression using variables of the alcohol history 
(length of sobriety, duration of drinking, lifetime ethanol 
consumption, average drinks per day), native liver histology, 
and posttransplant liver injury tests was used to identify 
markers of relapse after transplantation. Daily ethanol con-
sumption was significant when all 16 patients were consid-
ered (P=0.03), and marginally significant when only the 13 
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TABLE 4. Causes of death or graft failure after 6 months (first graft only) (n=35) 
Cause of death 
Cardiovascular 
Suicide 
PTLD 
Recurrent HCC 
New malignancy (invasive carcinomas) 
Infection 
Hepatic encephalopathy 
Unknown 
Graft failure without death 
Graft disease 
HCV +cr+strictures (1) 
HCV (1) 
chronic bile duct injury (1) 
HCV+cr 
No evidence 
Hepatic artery thrombosis 
Biliary strictures 
HCV 
Patient number 
(%) 
3 (9) 
1 (3) 
2 (6) 
3 (9) 
7 (20) 
5 (14) 
1 (3) 
7 (20) 
3 (9) 
2 (6) 
1 (3) 
Time range 
(days) 
1805-2351 
370 
783,1841 
265-1316 
577-2169 
236-2100 
1602 
198-2636 
1126-1339 
291,1731 
1604 
Comments 
upper aerodigestive (5) 
lung (1) 
uncertain primary (1) 
lung (3) 
abdomen (1) 
infected thrombus (1) 
post-TIPSS encephalopathy 
transitional cell carcinoma (2) 
HCC, hepatocellular carcinoma; HCV, hepatitis C infection; cr, chronic rejection; strictures, bile duct strictures; PTLD, posttransplant 
lymphoproliferative disorder; TIPSS, transjugular intrahepatic portosystemic shunt. 
TABLE 5. New extrahepatic malignancies after transplantation 
Primary Histology Number of tumors in Histology Number of tumors in 
alcohol cohort control cohort 
Upper aerodigestive Squamous 8 Squamous 2 
Genitourinary Transitional cell (4), Prostate 6 Prostate adenocarcinoma 3 
adenocarcinoma (2) 
Lung Squamous (2), Small cell (1) 3 Adenocarcinoma 2 
Colorectal Adenocarcinoma 2 Adenocarcinoma 3 
Hematological (not PTLD) Follicle centre cell lymphoma 1 Acute myeloid leukaemia 1 
Unknown Clear cell carcinoma 1 Adenocarcinoma 1 
Other 0 Breast adenocarcinoma (1), 3 
Thyroid papillary (1), Duodenal 
Kaposi sarcoma 
Skin Squamous (10), Basal cell 12 Squamous (2), Basal cell (5), 9 
(1), Melanoma (1) Melanoma (1), Kaposi (1) 
Total 33 (27/123pts) 24 (24/390pts) 
relapse-confirmed patients were considered (P=0.09). At re-
lapse, the serum GGTP:ALP ratio was elevated compared 
with nonrelapsers, whether the 13 known or the 16 known! 
suspected group was analyzed (relapsers vs. nonrelapsers: 
1.13 vs. 0.63, median; P=0.017). Other factors analyzed, in-
cluding steatosis and Mallory bodies in the native liver, du-
ration of pretransplant sobriety, and estimated lifetime eth-
anol consumption, were not significant. 
Allograft biopsies before relapse (12 patients) were not 
suspicious for alcohol injury. Seven of 13 patients had liver 
biopsies after relapse (1-10 biopsies, 2 weeks-4 years), of which 
only four had histology (mildly) suspicious for alcohol injury 
(Table 6). No patient had clear-cut alcoholic hepatitis. Only one 
patient had evidence of progressive fibrosis due to alcohol inju-
ry-moderate centrilobular pericellular fibrosis, 4.5 years after 
relapse. However, interpretation of the cause of fibrosis was 
complicated by concurrent hepatitis C infection and rejection-
related central venulitis during this interval. 
Although progressive alcohol injury was generally not seen 
in biopsies from relapse patients, they had other progressive 
liver disease; all five patients who were anti-hepatitis C-pos-
itive before transplant developed recurrent viral hepatitis, 
with four showing progressive fibrosis (maximum modified 
Chronic Hepatitis Fibrosis scores (10): 3/6 in two and 5/6 in 
the other two), and the 5th showing de novo hepatitis B on 
latest biopsy (2543 days after transplant). 
Four of the 13 confirmed relapse patients required hospital 
admission for noninfectious complications related to drink-
ing, including acute alcohol toxicity, acute rejection after 
noncompliance, alcohol-related polyneuropathy, and recur-
rent acute pancreatitis. Poor compliance with immunosup-
pressive therapy was noted for three severely relapsing pa-
tients, two of whom developed chronic rejection in addition to 
recurrent hepatitis C with fibrosis. Four confirmed relapse 
patients died (321-2273 days after transplant): three from 
infection and one from a ruptured intracranial aneurysm. 
Follow-up of the surviving nine confirmed relapse patients 
ranged from 2265 to 2931 days. Of the three patients suspi-
cious for relapse based on histology alone, one died (sepsis, 
2019 days), and two survived (at 2711 and 2737 days 
follow-up). 
Other Causes of Allograft Dysfunction 
One hundred nineteen allografts (97%) had primary func-
tion. Twenty-six (22%) patients developed major biliary or 
vascular complications. These included 3 (2%) with biliary 
anastomotic leaks and 16 (13%) with bile duct strictures, of 
which 4 were associated with hepatic artery stenosis or 
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TABLE 6. Histopathological findings in allograft biopsies obtained after alcohol relapse 
Patient 
1 
2 
3 
4 
5 
6 
7 
Days after 
transplant 
210 
465 
443 
1115 
1364 
2288 
2805 
Features suspicious for 
alcohol injury 
None 
Steatosis, rare Mallory 
Marginal 
steatohepatitis 
Mild steatofibrosis 
Steatosis 
None 
None 
Coexistent Alcohol injury on later biopsies graft disease 
HCV;cr No (autopsy liver: 321 days) 
HCV No (771, 946, 2300 days) 
HCV; cr Moderate pericellular fibrosis (1812 days) 
None No (1521, 1581 days) 
HCV Marginal steatohepatitis (2543 days) 
None N/A 
HCV N/A 
Allograft biopsies suspicious for alcohol injury, from patients without other evidence for relapse 
1 
2 
3 
1098 
1193 
1281 
Steatosis 
Mild steatofibrosis 
Steatosis, rare Mallory 
None 
None 
None 
No (1393, 1544 days) 
N/A 
Marginal steatohepatitis (1968 days) 
Steatosis, centrilobular steatosis; Mallory, centrilobular Mallory's bodies; Marginal steatohepatitis, steatosis with minimal acute inflam-
mation, borderline for low grade steatohepatitis; Steatofibrosis, steatosis with perivenular and pericellular fibrosis, suggestive of inactive 
steatohepatitis; cr, chronic rejection. 
thrombosis. Eleven patients (9%) developed allograft artery 
stenosis or thrombosis, and one developed portal vein throm-
bosis related to a chronic inflammatory pancreatic mass. We 
sought pretransplant factors that predicted these major bil-
iary/vascular complications: univariate analyses identified 
high estimated lifetime (P=O.OOOI) and daily (P=0.0008) 
ethanol consumption. In addition, donor age (P=0.03; 
younger donor = fewer complications) and lifetime ethanol 
consumption were only marginally significant in a bivariate 
model (P=O.11 without an influential outlier). The duration 
of sobriety pretransplant, hepatitis C serology, and various 
native liver histological parameters were not predictive. 
Biopsy-proven acute rejection affected 71 (60%) function-
ing allografts and was of moderate or severe intensity in 19 
(16%). Forty-five (38%) patients had only a single acute re-
jection episode (range 1-5 episodes). The first rejection epi-
sode occurred later in patients with longer pretransplant 
sobriety (P<O.02). Chronic rejection affected three patients 
(2%) (321-1135 days), all of whom had poor compliance with 
the recommended immunosuppression. However, there was 
no significant difference in the rate oflate-onset (>6 months) 
acute or chronic rejection between alcoholic patients that 
relapsed and those that did not or between the alcoholic 
cohort and the nonalcoholic controls (data not shown). 
Sixteen (13%) patients showed chronic bile duct injury on 
biopsy. Proportional hazards regression using time-depen-
dent covariates was used to evaluate the maximum and 
minimum liver biochemistry values during serial 6-month 
intervals after transplantation. Patients with chronic bile 
duct injury on liver biopsy had higher maximum and mini-
mum GGTP (P<O.OOI and 0.0001, respectively), SGOT 
(P<0.04 and 0.01, respectively), and higher minimum SGPT 
(P<0.05), compared with other transplanted alcoholics with-
out chronic bile duct injury. The predictors of chronic bile 
duct injury were hepatitis C infection (P<0.04), and pericel-
lular fibrosis on biopsy (P<O.Ol). Four (3%) patients had 
Cytomegalovirus graft infection (38-169 days). 
Twenty patients showed hepatitis B or hepatitis C infec-
tion after transplant (Table 7). Hepatitis C recurred in 14 of 
19 patients seropositive before transplant and was diagnosed 
on biopsy with positive serology-with confirmatory RT-PCR 
or branched chain DNA assays in 9 of 14 cases. Nine of 14 
patients with recurrent hepatitis C developed fibrosis stage 3 
(of 6) or worse on biopsy, including two stage 5 and one 
cirrhosis. Two additional patients developed hepatitis C an-
tibodies after transplantation and showed hepatitis without 
fibrosis on biopsy (679, 1859 days; donor serology was nega-
tive). Fibrosis in hepatitis C infection progressed faster in 
relapsers compared with nonrelapsers, but numbers were 
small and the difference was not significant. 
Patients who underwent transplantation for alcoholic liver 
disease alone had fewer graft biopsies than nonalcoholic con-
trols transplanted for hepatitis C disease (median 4 vs. 6 per 
patient, P=O.009). Moreover, hepatitis C-seropositive alco-
holics had more graft biopsies than hepatitis C seronegative 
alcoholics (median eight vs. four per patient, P=0.0107). 
Hepatitis B recurred in the patient with hepatitis B surface 
antigen pretransplant and affected five patients who were 
seronegative pretransplant (donor serology was negative). 
Since liver allograft biopsies in our population are carried out 
largely because of liver allograft dysfunction, the above re-
sults are at least one way of showing that recurrent hepatitis 
C disease has a greater impact on allograft dysfunction than 
recurrent alcohol abuse. 
In a univariate model, viral hepatitis in the allograft was a 
marginally significant predictor of allograft failure, although 
numbers were small (hepatitis C alone: P=0.07; hepatitis C 
or hepatitis B: P=O.073). Multiple regression analyses for 
independent predictors of graft failure identified develop-
ment of "mechanical" biliary or vascular complications 
(P=O.Ol); chronic bile duct injury on biopsy (P=O.002), and 
pericellular fibrosis on biopsy (P<0.05). When analyses of 
outcomes were repeated comparing those with lifetime etha-
TABLE 7. Viral hepatitis after transplant (20 patients) 
Infection 
HBV, recurrent 
HBV, new onset 
HCV, recurrent 
HCV, new onset 
Number of 
patients 
1 
5 
14 
2 
Diagnosis (days 
after transplant) 
1163 
169-2543 
45-1364 
679, 1859 
Maximum modified HAl 
fibrosis score on biopsy 
3 
0-6 
0-6 
o 
(note: 2 patients developed both HBV and HCV graft infection) 
HAl, hepatitis activity index; HBV, hepatitis B; HCV, hepatitis C. 
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nol consumption ~SMM kg vs. <600 kg (men) or ~1RM kg vs. 
<150 kg (women) with those with daily ethanol consumption 
~SM g vs. <60 g (men) or ~OM g vs. <20 g (women) there were 
no significant differences. 
DISCUSSION 
Patients with cirrhosis and a history of excessive alcohol 
use are labeled as having alcoholic liver disease, a term that 
may inappropriately combine a sociaVpsychiatric designation 
with a statement of etiology for liver disease. Two main 
reasons explain the difficulties in estimating the contribution 
of alcohol to cirrhosis. First, micronodular cirrhosis may 
evolve toward a macronodular pattern (12). In such cases, 
which are often without earlier biopsy, the final histology 
might be indeterminate for cause. Second, at least 31% of the 
patients in this and other studies had coexistent conditions 
that alone could have been the indication for liver transplan-
tation (7, 13-18). Indeed, native livers from hepatitis C-in-
fected patients here and in other studies often showed mor-
phology of chronic hepatitis rather than alcohol injury (Table 
1), suggesting that alcohol had exacerbated viral damage 
rather than the other way around (19,20). In alcoholics, the 
presence and severity of clinical liver disease correlate with 
hepatitis C seropositivity (17, 21); alcohol may increase hep-
atitis C replication and liver injury (22) and accelerate fibro-
sis (23). Hence, such cases might be better regarded as a 
subgroup of the coexistent diagnosis (hepatitis C) rather than 
alcohol liver disease, especially when considering the impact 
of pretransplant diagnosis on graft outcome. 
Alcoholic liver disease is cured by transplantation, but a 
legacy of social and systemic injury remains. The most serious 
medical predisposition is to malignancy (24), which was com-
mon-particularly aerodigestive carcinomas-and caused 
death in this and other studies (25-28). This is likely attribut-
able to heavy smoking in addition to alcohol problems; however, 
we were unable to obtain smoking histories in both the study 
subjects and controls. Regardless, thorough otorhinolaryngol-
ogy screening should be carried out before listing alcoholic pa-
tients for transplantation (27). 
In contrast to some reports (27,29) and its frequent use as 
a screening criterion (30, 31), pretransplant sobriety shorter 
than 6 months did not predict relapse in this or in previous 
studies at our center (34) and elsewhere (32-36). In our 
cohort, daily ethanol consumption better predicted relapse, 
perhaps because it better indicates the severity of addiction 
(37). No explant histological feature in this or another (38) 
study predicted relapse, unlike with Conjeevaram et a1., who 
correlated Mallory bodies with relapse (16). The finding of 
many Mallory bodies in 16% of explants in the Conjeevaram 
study (16), compared with small foci in 33% explants here, 
suggest different pretransplant drinking behaviors. 
The contribution of relapse to morbidity after transplanta-
tion has proved difficult to define (14, 39). Prospective studies 
show relapse in 34% to 95% of selected patients (14, 32, 40), 
and we have started a prospective study of alcohol use after 
transplant for alcoholic liver disease. Here we probably un-
deridentified relapse; we relied largely on liver injury test 
abnormalities, patient reports of alcohol use, blood alcohol 
tests, and clinical suspicion through drinking patterns that 
could not be concealed. For less severe consumption, covert 
drinking may be difficult to detect. 
Hepatic manifestations of relapse might include alcoholic 
liver disease, alcohol exacerbation of coexistent conditions 
such as hepatitis C, or late-onset acute or chronic rejection 
because of noncompliance (41). Here, recurrent alcohol liver 
disease was limited to steatosis (42) and was not responsible 
for progressive fibrosis. These results compare favorably 
with others: allograft alcoholic hepatitis and cirrhosis after 
relapse are well described (5, 16, 43, 44), but are uncommon 
and rarely cited as a significant cause of graft failure (6, 27, 
30). Steatosis affected fewer than 10% of patients after 7 
years follow-up, compared with much higher recurrence 
rates for autoimmune liver diseases or viral hepatitis (15-
25% and >50%, respectively), with a proportion of the latter 
developing cirrhosis by that time. The possibility that alcohol 
relapse might accelerate hepatitis C-related fibrosis in allo-
grafts needs further study. Such studies should evaluate 
both alcoholic and nonalcoholic hepatitis C-infected patients 
(7,42, 45-47), because nonalcoholic recipients report alcohol 
use after transplant as frequently as alcoholic ones (48). Late 
onset acute and chronic rejection attributable to poor compli-
ance was a manifestation of heavy relapse, as reported (30), 
but was uncommon in this and other studies of those trans-
planted for alcoholic liver disease (5, 30, 49). Indeed, late-
onset acute and chronic rejection were not significantly more 
common in relapsers than in nonrelapsers or in alcoholics 
versus nonalcoholic controls. 
The infrequency of alcoholic liver disease after transplan-
tation could be due to effective recipient screening, alcohol 
abuse short of the threshold needed for liver disease, short 
follow-up (50), factors that render the new liver alcohol-
resistant, or any combination of these. Determinants of the 
alcohol threshold for liver disease probably include liver-
intrinsic properties, because only about 20% of alcohol abus-
ers develop clinical liver disease (21, 51, 52). There is a 
genetic predisposition to alcohol-related cirrhosis (53), per-
haps involving polymorphic genes that also influence drink-
ing behavior (54, 55), such as mitochondrial aldehyde dehy-
drogenase (56, 57). Study of relapsing alcoholic patients who 
do and do not develop alcoholic liver disease in the allograft 
might facilitate identification/understanding of allelic regu-
lators of progressive alcohol-related liver injury. 
Although recurrent alcohol liver disease was not a prob-
lem, heavy relapse clearly imposed health problems, re-
flected by admissions for noninfective complications and 
deaths from systemic infections (15,27,30,39,49,58). Even 
so, our results are similar to other studies in which only 10% 
to 13% of patients had alcohol relapse that caused physical 
morbidity or mortality (59, 60). More importantly, this study 
reaffirms the good graft and patient survival of those trans-
planted for alcoholic liver disease, comparable with results in 
other liver diseases (7), and support our continuing relatively 
"liberal" selection policy. 
We were able to identify clinical and histological factors 
predictive of graft failure. Major biliary and vascular compli-
cations are not surprising, while biopsy evidence of pericel-
lular fibrosis or focal chronic bile duct injury is more subtle, 
but nonspecific, evidence of significant graft injury. Focal 
chronic bile duct injury has also been associated with hepa-
titis C infection before (61, 62), as we found here. 
Past studies have found a lower acute rejection incidence in 
transplanted alcoholics, compared with other disease indica-
tions (63,64), but more detailed correlations within the alcohol 
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group have not been reported. The present suggestion that long 
pretransplant sobriety is associated with freedom from early 
acute rejection is nevertheless difficult to rationalize. 
In conclusion, alcoholism is a brain-centered addictive dis-
order in which people submit themselves to an alcohol-rich 
environment that can damage many tissues. Those present-
ing for liver transplantation might seem to be preselected for 
proclivity to alcohol-induced liver disease, but this study 
shows that up to 30% have coexistent diseases that alone 
could have necessitated liver transplantation. We found re-
current alcohol liver disease to be a relatively benign disorder 
by comparison with recurrent viral and autoimmune liver 
disease and not an important cause of graft failure. Never-
theless, heavy relapse in a minority of patients can shorten 
survival, primarily through infectious complications, and 
may accelerate progression of recurrent viral hepatitis. 
Thus, in those without coexistent conditions, alcoholic liver 
disease is an excellent indication for liver transplantation. A 
new liver introduces a new genetic variable, which could 
potentially delay recurrent liver disease, even in severe 
relapse. Our data are insufficient to determine whether 
this is true, but consistent with the hypothesis. However, 
chronic alcohol-induced and other addictive behavior-in-
duced injury (e.g. smoking) of other target continues to 
evolve, of which carcinogenesis may be accelerated by im-
munosuppression (65). Hence, patients should be heavily 
screened for other target organ damage, which is a greater 
cause of morbidity and mortality than recurrent alcohol 
liver disease. 
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